Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesClinical/Medical PolicyOscar Health B-Hemolytic Streptococcus Coverage | …
    Ask Trek AI about this page
    CurrentOscar HealthPolicy AHS-G2035

    B-Hemolytic Streptococcus Testing

    Customize your policy alerts

    Sign up for Oscar Health Policy AHS-G2035 alerts

    Get alerted when Policy AHS-G2035 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Defines coverage criteria, indications, and limitations for laboratory testing to detect beta-hemolytic streptococcal infections (including Groups A, B, C, G) for Oscar Health members and guidance for providers on claims and documentation.

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Policy Summary
    PayerOscar Health
    PolicyB-Hemolytic Streptococcus Testing
    Policy CodePolicy AHS-G2035
    Change TypeNo material change
    Effective DateOct 1, 2026
    Last ReviewJun 16, 2026
    Next Review DateJun 16, 2026
    Key ActionIf a symptomatic child >3 years has a negative rapid antigen test, obtain a throat culture or perform a NAAT (dual swab collection recommended to enable reflex testing).
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    Centor ≥3threshold for throat culture testing
    RADT negative (child)reflex to culture indication
    ~85%RADT sensitivity (pooled pediatrics)
    ~97-98%NAAT sensitivity
    Panel testsNot meeting criteria

    Coverage Criteria for B-hemolytic Streptococcus Testing

    Detection of streptococcal infection causing respiratory illness (throat culture)

    Covered when ANY of the following are met:

    Throat culture indications: a) Modified Centor score of 3 or greater; b) Suspected bacterial pharyngitis in the absence of viral features (e.g., cough, oral ulcers, rhinorrhea); c) Following a negative rapid antigen diagnostic test (RADT) in a symptomatic child or adolescent.Centor score >= 3

    Centor criteria components and RADT reflex guidance referenced in Notes and Scientific Background

    Skin and soft tissue infections

    Covered when ALL of the following are met:

    Skin/soft tissue culture: Bacterial culture testing for streptococcal infection from a skin swab or from pus meets criteria.

    Culture description and rationale (CDC gold standard) provided in Scientific Background

    Suspected acute rheumatic fever (ARF) or post-streptococcal glomerulonephritis (PSGN)

    Covered when ANY of the following serologic tests are ordered for suspected ARF or PSGN:

    Serologic testing for ARF/PSGN: a) Serological titer testing (acute and convalescent titers); b) Anti-streptolysin O (ASO) immunoassay; c) Hyaluronidase activity or anti-hyaluronidase immunoassay; d) Streptokinase activity or anti-streptokinase immunoassay.

    Rising ASO/anti-DNase B between acute and convalescent samples is best evidence of antecedent infection; ASO peaks ~3–5 weeks, ADB ~6–8 weeks

    Not covered / Does not meet criteria

    Tests or situations explicitly listed as not meeting criteria:

    RADT not covered situations: Except for asymptomatic children under age 3 with mitigating circumstances (eg, symptomatic household member), RADT does NOT meet criteria when used as: a) a follow-up test after a bacterial culture or a nucleic acid test; or b) a screening method in an asymptomatic patient.
    General serology and enzymatic assays: For all situations not otherwise meeting criteria, serological titer testing, anti-streptolysin O immunoassay, hyaluronidase/anti-hyaluronidase, and streptokinase/anti-streptokinase immunoassays DO NOT MEET CRITERIA.
    Panel and quantitative NAATs: Panel tests that screen and identify multiple streptococcal strains (eg, Solana Strep Complete, Lyra Direct Strep Assay), quantification of streptococcal strains by nucleic acid amplification (including PCR), and certain enzymatic (eg, NADase) assays DO NOT MEET CRITERIA.
    Duplicate organism probes: Simultaneous ordering of both direct probe and amplification probe for the same organism in a single encounter DOES NOT MEET CRITERIA.

    Guideline-driven testing criteria

    Guideline-recommended testing and documentation behaviors (CDC, AAP, AHA) summarized as rule-sets

    Pediatric testing when pharyngitis suspected: Children with acute sore throat and clinical findings suggestive of GAS (fever, tonsillar exudate, tender anterior cervical nodes, absence of viral features) should be tested with RADT; if RADT is negative in children >3 years, obtain a throat culture (or NAAT) and have a mechanism to notify family if back-up culture returns positive.

    Sources: CDC, AAP

    Do not test when viral features or age <3: Do not test children with obvious viral symptoms (rhinorrhea, cough, hoarseness, oral ulcers, conjunctivitis) or children younger than 3 years in most circumstances; avoid routine testing of asymptomatic household contacts except when contacts are at increased risk of sequelae.

    Source: AAP

    Use of NAAT or RADT: A positive RADT or throat culture confirms GAS pharyngitis; NAATs and POC molecular assays have higher sensitivity and may be used as stand-alone diagnostic tests in many settings, recognizing assay-specific limitations in differentiating streptococcal groups.

    Sources: CDC, IDSA, assay performance summaries

    Guideline-based testing criteria

    Relevant clinical testing recommendations from cited guidelines (not an exhaustive policy decision set in this part):

    GBS obstetric screening: All pregnant women should undergo antepartum screening for GBS at 36 0/7–37 6/7 weeks unless intrapartum antibiotic prophylaxis is already indicated due to GBS bacteriuria during pregnancy or prior GBS-infected newborn.

    ACOG Committee Opinion #797

    GAS pharyngitis testing criteria: Test patients with high clinical suspicion for GAS when there is an intention to treat; do not test patients with modified Centor <3 or with viral features (rhinorrhea, cough, oral ulcers, hoarseness).Centor score >=3 typical

    ICSI consensus

    Use of rapid antigen and NAAT: In pediatric patients, a negative direct antigen test known to have sensitivity <80% should be followed by NAAT or culture; direct and amplified NAATs are more sensitive and negative NAAT results do not require secondary arbitration.

    IDSA guidance

    Panel or multiplex assays that screen for multiple streptococcal strains, assays that report quantitative results of streptococcal organisms by nucleic acid amplification (including PCR), and certain enzymatic/antibody-based assays are explicitly listed as not meeting criteria. Examples called out in the policy include multi-organism panels such as the Solana Strep Complete Assay and Lyra Direct Strep Assay, quantification of streptococcal strains by NAAT/PCR, and nicotinamide-adenine dinucleotide activity assays or corresponding immunoassays. Claims for these tests may be subject to noncoverage because the evidence does not establish that they are required or beneficial for diagnosis or treatment.

    The AAP guidance cited in the policy indicates that testing children younger than 3 years generally is not indicated for GAS pharyngitis in industrialized countries due to the very low risk of rheumatic fever. The AAP also advises that home use of FDA-cleared rapid tests is discouraged because of the risk of false-positive results representing colonization rather than true infection.

    Guideline sources referenced by the policy recommend against routine microbiologic testing in certain outpatient pneumonia settings: the ATS/IDSA guideline advises not to obtain sputum Gram stain and culture routinely and not to obtain blood cultures routinely for adults with outpatient community-acquired pneumonia. The pediatric PIDS-IDSA guidance similarly advises against routine blood cultures in nontoxic, fully immunized children with outpatient CAP and limits sputum culture/Gram stain to hospitalized children who can produce sputum or children who fail to improve.

    No additional explicit exclusions are stated in the provided publication-history or governance chunks beyond those enumerated elsewhere in the policy document.

    For indications and situations not described as meeting criteria, the policy states that serologic and enzymatic assays such as the antistreptolysin O (ASO) immunoassay, hyaluronidase activity or anti-hyaluronidase immunoassay, and streptokinase activity or anti-streptokinase immunoassays do not meet criteria and therefore are not covered for routine diagnostic use.

    The policy follows guideline recommendations that testing asymptomatic individuals and children with clear viral features (for example, rhinorrhea, cough, hoarseness, oral ulcers, conjunctivitis) is not recommended and is therefore generally considered not medically necessary for diagnosis of GAS pharyngitis.

    The NICE assessment cited in the policy concludes that rapid tests for group A streptococcal infection are not recommended for routine adoption for people with sore throat because they offer limited additional benefit over clinical scoring alone in terms of improving prescribing, stewardship, or patient outcomes.

    Within the portions of the document provided for review there are no additional explicit statements labeled as 'not medically necessary' beyond the items already referenced in the policy excerpts.

    Coding and Procedure Codes

    Applicable coding guidancemixed
    No codes listed
    Microbiology / serology / culture CPTsCPT
    86060Antistreptolysin O; titer.
    86063Antistreptolysin O; screen.
    86215Deoxyribonuclease, antibody.
    86581Culture, bacterial; any other source except urine, blood or stool, aerobic, with isolation.
    87070Culture, bacterial; quantitative, aerobic with isolation and presumptive identification of isolates, any source except urine, blood or stool.
    87077Culture, bacterial; aerobic isolate, additional methods required for definitive identification, each isolate.
    87081Culture, presumptive, pathogenic organisms, screening only.
    NAAT / antigen CPTsCPT
    87651Infectious agent detection by nucleic acid (DNA or RNA); Streptococcus, group A, direct probe technique.
    87652Infectious agent detection by nucleic acid (DNA or RNA); Streptococcus, group A, amplified probe technique / quantification (as listed).
    87797Infectious agent detection by nucleic acid (DNA or RNA), not otherwise specified; direct probe technique, each organism.
    87798Infectious agent detection by nucleic acid (DNA or RNA), not otherwise specified; amplified probe technique, each organism.
    87799Infectious agent detection by nucleic acid (DNA or RNA), not otherwise specified; quantification, each organism.
    87880Infectious agent antigen detection by immunoassay with direct optical (i.e., visual) observation; Streptococcus, group A.
    FDA 510(k) / device identifiers referencedmixed
    K162274510(k) premarket notification of intent to market Solana Strep Complete Assay (FDA) (2016).
    K183366510(k) Substantial Equivalence Determination Desion Summary (FDA).
    K201269Groups A, C And G Beta-Hemolytic Streptococcus Nucleic Acid Amplification System (FDA).
    Centor criteria — score ≥ 3
    ThresholdCentor score ≥ 3
    ComponentsOne point each: tonsillar exudates; tender anterior cervical lymphadenopathy; fever; absence of cough
    UsePatients scoring ≥3 can be tested for GAS pharyngitis (throat culture or RADT/NAAT per policy)

    Provider Actions, Authorization, and Documentation

    Prior Authorization

    Authorization tied to member benefits

    Coverage and reimbursement for streptococcal testing are subject to the member’s benefit coverage and applicable regulations at the time of service; services must meet authorization and medical necessity guidelines for the procedure, diagnosis, and member’s state of residence.

    • Verify member benefits and any authorization requirements prior to ordering testing.
    • Ensure testing and coding align with the member’s state residency and applicable regulations.
    Prior Authorization

    No explicit prior authorization specified in policy excerpts

    The policy text and supporting clinical evidence discuss assay performance and workflows but do not state any specific prior authorization requirements for streptococcal assays in the provided excerpts.

    • Documented clinical utility and comparative performance of NAAT/HDA assays are presented, but no Oscar-specific PA rules are listed in these chunks.

    Background and Rationale

    Group A Streptococcus (GAS) is identified in the policy as the most common bacterial cause of acute pharyngitis; Groups C and G streptococci can produce clinically similar pharyngitis. The policy references culture, RADT, NAAT, serology, and MALDI-TOF as laboratory methods used for identification, and notes that the Centor clinical criteria help determine testing need (a Centor score of ≥3 is the typical threshold prompting testing).

    Definitions and Key Terms

    Centor criteria — Clinical score
    DefinitionClinical score with one point each for tonsillar exudates, tender anterior cervical lymphadenopathy, fever, and absence of cough
    Scoring actionScore used to assess likelihood of GAS pharyngitis; score ≥3 indicates testing is warranted
    Clinical implicationPatients with score <3 are unlikely to have GAS and generally do not require strep testing or antibiotics
    RADT — Rapid antigen diagnostic testing
    DefinitionRapid antigen diagnostic testing (RADT): point-of-care or laboratory antigen detection tests for Streptococcus
    PerformanceVariable sensitivity and specificity; many commercial RADTs exist with differing accuracy
    Policy Summary
    PayerOscar Health
    PolicyB-Hemolytic Streptococcus Testing
    Policy CodePolicy AHS-G2035
    Change TypeNo material change
    Effective DateOct 1, 2026
    Last ReviewJun 16, 2026
    Next Review DateJun 16, 2026
    Key ActionIf a symptomatic child >3 years has a negative rapid antigen test, obtain a throat culture or perform a NAAT (dual swab collection recommended to enable reflex testing).
    SourceLink
    On This Page
    Coverage Criteria for B-hemolytic Streptococcus TestingCoding and Procedure CodesProvider Actions, Authorization, and DocumentationBackground and RationaleDefinitions and Key Terms
    Document antecedent infection for sequelae: For suspected post-streptococcal conditions (eg, PSGN, ARF), document laboratory evidence of preceding GAS infection via rising ASO or anti-DNase B titers, or positive throat culture/RADT.

    Source: AAP, AHA

    GBS in pregnancy: Antepartum screening for GBS at 36 0/7–37 6/7 weeks is recommended and PCR-based testing may guide intrapartum prophylaxis; perform susceptibility testing for GBS isolates from penicillin-allergic pregnant women.

    Sources: ACOG, ASM

    Invasive disease diagnosis: Early-onset GBS is diagnosed by blood or CSF culture; late-onset diagnosis is based on clinical signs and isolation from sterile sites; routine labs (eg, CBC, CRP) are poor predictors in well-appearing infants.

    AAP

    Billing Rule

    Referenced procedure codes may be subject to payer rules

    Procedure codes listed in Section VIII are referenced by the policy and may be subject to payer-specific prior authorization or billing rules; verify Oscar Health requirements before submitting claims.

    • Codes included in Section VIII: 86060, 86063, 86215, 86581, 87070, 87077, 87081, 87651/87652 (NAAT), 87797–87799, 87880.
    • Confirm whether any of these CPT/HCPCS codes require prior authorization under the member’s plan.
    Prior Authorization

    No general prior authorization requirement stated

    The provided policy excerpts do not impose a general prior authorization requirement for streptococcal testing.

    • If payer-specific PA applies, it will be detailed outside the excerpted policy sections—check member documents and Oscar Health portals.
    Step Therapy

    Two-step testing workflow for pediatric pharyngitis (collect dual swab)

    For pediatric patients, if a less-sensitive RADT is negative, follow-up testing with a more sensitive NAAT or throat culture is recommended; collecting a dual swab at the initial visit is a suggested workflow to enable reflex testing.

    • Collect dual swab specimens initially so the second swab can be used for NAAT or culture if RADT is negative.
    • Have a mechanism to notify the family and initiate antibiotics if the backup culture/NAAT returns positive.
    Step Therapy

    Two-step testing in pediatrics per CDC/guidelines

    CDC and guideline-based guidance endorse a two-step pediatric pathway: in children older than 3 years, a negative RADT should be followed by throat culture (or NAAT); ensure backup testing is available and families can be contacted with positive results.

    • Follow CDC guidance to obtain throat culture when RADT is negative in children >3 years.
    • Ensure processes are in place to contact families and start antibiotics if backup testing is positive.
    Denial Risk

    No additional denial triggers listed in excerpts

    No explicit denial triggers beyond those related to noncoverage of tests listed as 'DO NOT MEET CRITERIA' and failure to follow government policy are detailed in the excerpts.

    • Primary denial risks derive from ordering noncovered assays or failing to comply with payer/government coverage rules.
    Step Therapy

    No insurer step therapy requirements specified

    No step therapy requirements are specified in the policy excerpts; the document instead describes recommended testing algorithms (eg, RADT → culture/NAAT in children) rather than insurance-imposed step therapy.

    • Follow guideline-recommended diagnostic algorithms, but do not assume formal payer step therapy mandates are present unless specified in member benefits.
    Documentation Required

    Documentation and medical necessity required on claims

    Providers are responsible for submitting accurate documentation supporting medical necessity; services must meet authorization and medical necessity guidelines and be coded per industry-standard coding guidance.

    • Include clinical indication (eg, modified Centor score, presence/absence of viral features) and relevant signs/symptoms in the medical record when ordering testing.
    • Code claims in accordance with CPT/HCPCS and payer instructions to avoid denials or recoupment.
    Documentation Required

    Document laboratory evidence of antecedent GAS infection for sequelae

    When diagnosing suspected post-streptococcal sequelae (eg, PSGN or acute rheumatic fever), document laboratory evidence of preceding GAS infection such as isolation of GAS from throat or skin or elevated streptococcal antibody titers (ASO/anti-DNase B).

    • Include acute and convalescent antibody titers when relevant; note ASO peaks ~3–5 weeks and ADB peaks ~6–8 weeks after infection.
    • Retain laboratory reports showing positive throat culture, RADT, or NAAT as evidence of antecedent infection.
    Documentation Required

    Susceptibility testing for penicillin-allergic pregnant patients

    Perform antimicrobial susceptibility testing on GBS isolates from pregnant women with penicillin allergy and include reporting options for vancomycin when appropriate, per ASM guidance.

    • Order susceptibility testing for GBS isolates when the pregnant patient has documented penicillin allergy.
    • Ensure laboratory reports specify susceptibility and alternative agent recommendations (eg, vancomycin options).
    Note

    Evidence and guideline references provided for clinical decisions

    The policy’s evidence references and guideline citations are provided to support clinical and laboratory testing decisions; use the listed references (Section IX) and cited guidelines (CDC, AAP, AHA, IDSA, ASM) when determining appropriate testing workflows.

    • Refer to Section IX evidence-based references and cited guideline excerpts for clinical justification when ordering or documenting tests.
    • Use CDC/AAP guidance for pediatric RADT/backup culture workflows and ASM/ACOG guidance for GBS in pregnancy.
    Denial Risk

    Denial risk for noncovered tests or improper coding

    Claims may be denied or recouped if coding/billing guidelines or reimbursement policies are not followed; tests listed as 'DO NOT MEET CRITERIA' (for example, panel assays that screen multiple streptococcal strains, quantitative NAATs, and certain enzymatic/serologic assays) are subject to noncoverage.

    • Avoid ordering panel NAATs or quantitative nucleic acid amplification for streptococcal testing when policy states they DO NOT MEET CRITERIA (eg, Solana Strep Complete, Lyra Direct Strep Assay used as panel screening).
    • Review Section III exclusions before submitting claims to prevent denials or recoupments.
    Denial Risk

    Risk of missed diagnosis if pediatric RADT negative not followed by backup testing

    Failure to obtain or to follow-up a throat culture (or NAAT) after a negative RADT in children older than 3 years, when indicated, risks missed GAS diagnosis; ensure backup testing and a process to contact families for positive results.

    • Collect backup specimen or have reflex testing available when using RADT in children >3 years.
    • Document the mechanism to notify family and initiate antibiotics if backup testing is positive.
    Denial Risk

    Government policy supersedes policy where conflicts exist

    If there is a conflict between this Policy and applicable government policies (LCDs/NCDs/state Medicaid), the government policy will govern determinations; failure to follow applicable government policy may result in denial.

    • Check for relevant LCDs/NCDs or state Medicaid rules that may supersede this policy prior to ordering or billing.
    • Follow government coverage determinations where applicable.
    Note
    Pediatric workflowIn children, a negative RADT from a test with sensitivity <80% should be followed by NAAT or throat culture (collect dual swab option)
    NAAT — Nucleic acid amplification test
    DefinitionNucleic acid amplification test (NAAT): amplifies DNA/RNA to detect organisms; includes PCR and isothermal methods
    SensitivityGenerally more sensitive than antigen tests and antibody-based testing; some NAATs do not require secondary arbitration
    FormatsAvailable as point-of-care rapid molecular assays and lab-based NAATs; assay-specific selectivity and ability to differentiate groups varies
    RADT — Rapid Antigen Diagnostic Test
    DefinitionRapid Antigen Diagnostic Test (RADT): point-of-care or lab-based antigen detection methods including enzyme immunoassays, optical assays, and agglutination
    VariabilityNumerous commercially available RADTs with considerable variability in sensitivity and ease of use
    Pediatric recommendationIf RADT sensitivity <80% and test is negative in children, follow-up with NAAT or culture per CDC/AAP guidance
    NAAT — Nucleic Acid Amplification Test
    DefinitionNucleic Acid Amplification Test (NAAT): molecular assays (PCR, helicase-dependent amplification, others) that amplify DNA/RNA to detect streptococcal nucleic acids
    AdvantagesMore sensitive than antibody-based tests and many RADTs; negative direct NAAT results generally do not require secondary arbitration
    LimitationsAssay-specific differences in selectivity and ability to differentiate GAS vs GCS/GGS; some NAATs may be qualitative or quantitative
    MALDI-TOF — Matrix-Assisted Laser Desorption Ionization–Time of Flight
    DefinitionMALDI-TOF: Matrix-Assisted Laser Desorption Ionization–Time of Flight mass spectrometry used to identify bacteria from pure culture by spectral database matching
    UseRapid identification of cultured organisms once a pure colony is available; compares spectra to known database
    LimitationsFor less common organisms, MALDI-TOF may be inconclusive and require additional bench or molecular tests
    Late-onset GBS disease
    DefinitionLate-onset GBS disease: GBS disease occurring after the neonatal period diagnosed by isolation of group B streptococci from blood, CSF, or other normally sterile sites
    Clinical noteCan occur even if maternal antepartum screening was negative; adequate intrapartum prophylaxis does not prevent late-onset disease
    DiagnosisEvaluation should be based on clinical signs; diagnosis relies on isolation from sterile sites
    Laboratory evidence of preceding GAS infection (per AHA)
    DefinitionLaboratory evidence of preceding GAS infection (per AHA): increased or rising anti-streptolysin O or other streptococcal antibodies; positive throat culture for group A β-hemolytic streptococci; positive rapid GAS carbohydrate antigen test in high pretest probability cases
    Evidence standardA rise in antibody titer (acute to convalescent) is better evidence than a single titer result
    Clinical useUsed to support diagnosis of acute rheumatic fever and other post-streptococcal sequelae
    NAAT / molecular assays
    ScopeNAAT and rapid molecular assays referenced for detection of group A, B, C, and G streptococci in clinical evaluations and FDA summaries
    Regulatory contextMultiple FDA 510(k)-cleared NAATs exist for strep detection (eg, Lyra, Solana, others) with associated device summaries
    Clinical implicationNAATs vary by method (PCR, HDA) and performance characteristics; assay-specific limitations should guide test selection
    Clinical guidelines
    SourcesClinical guidelines cited include IDSA, CDC, AAP/Red Book, AHA, ACOG, ASM, NICE, and others
    Guideline roleGuidelines inform testing indications, pediatric two-step testing workflows, and obstetric GBS screening recommendations
    ExamplesGuidelines referenced: CDC/AAP for pediatric RADT/culture algorithm; ACOG for antepartum GBS screening; AHA for serologic evidence of antecedent GAS